Surprising blood cell finding could mean new diabetes treatment
Scientists have made a surprising discovery about the role of white blood cells, known as neutrophils, and the role they play in insulin resistance that leads to type 2 diabetes. The finding means a new target for treatment for the disease from drugs that are already being tested in the United States for emphysema and type 1 diabetes.
Neutrophils' role in mediating insulin resistance unexpected
The study, published in the journal Nature Medicine, unexpectedly revealed neutrophils that are abundant in the body mediate insulin resistance.
Researchers at the University of California, San Diego School of Medicine explain the blood cells’ role is to attack bacteria and other foreign invaders.
The white blood cells also secrete and enzyme known as neutrophil elastase (NE) that impairs insulin signaling and boosts resistance. The discovery was made by a team led by Jerrold M. Olefsky, MD, associate dean for scientific affairs at UC San Diego Health Sciences and professor of medicine who studied liver and fat cells from mice and humans and live mouse models.
"These results are largely unexpected," said Da Young Oh, an assistant project scientist in Olefsky's lab and study co-author in a media release. "Although several immune cells have been established in the etiology of insulin resistance, the role of neutrophils in this process has remained unclear until now."
One of the reasons insulin resistance happens is from chronic low-grade inflammation that is common in fat tissue and why obesity is a top risk factor for type 2 diabetes.
Neutrophils are the first line of defense when inflammation occurs. The white cells recruit other cells in the body known as macrophages when an inflammatory process occurs, like the kind associated with obesity.